Tiny AgTech Firm Becomes First Avalanche Treasury Play on Nasdaq

After announcing a $550M capital raise and a rebrand, this microcap is now the first Nasdaq-listed company to commit to building an Avalanche treasury with backing by crypto heavyweights like HiveMind, Galaxy, and Scaramucci.

On Behalf of First Majestic Silver Corp.

Silver isn’t just a precious metal anymore.

It’s now a critical mineral, essential for EVs, solar, and defense systems.

That means demand is surging. And governments are stockpiling.

Yet while thousands of silver juniors chase a discovery, only a handful actually produce silver.

This company is one of them with four active mines delivering more than 30 million silver-equivalent ounces a year.

And it’s not standing still. At its flagship mine, it installed the industry’s first High-Intensity Grinding mill that is boosting recoveries to 94%. That’s world-class efficiency.

Last quarter:

But here’s the catch. Despite being a proven producer, it’s still priced like a junior.

Under $10 a share.

The setup is extraordinary. Silver is climbing. Institutions are loading ETFs. Supply is tight.

History shows what happens next. In 2011, silver climbed 175%. Producers outperformed the metal.

This company is entering that same setup with better technology, stronger margins, and growing production.

Get the report before Wall Street catches on.

*Examples that we provide of share price increases pertaining to a particular Issuer from one referenced date to another represent an arbitrarily chosen time period and are no indication whatsoever of future stock prices for that Issuer and are of no predictive value. Our stock profiles are intended to highlight certain companies for YOUR further investigation; they are NOT stock recommendations or constitute an offer or sale of the referenced securities.

Wall Street extended its rally as investors priced in further rate cuts and piled into big tech, with Nvidia and Apple leading gains on bullish headlines.

Nvidia (NASDAQ: NVDA) just made a jaw-dropping move, pledging up to $100 billion into OpenAI.

That means not only cash, but at least 10 gigawatts of GPUs heading into OpenAI’s next generation of AI models starting in 2026.

This is not a partnership; it is Nvidia positioning itself firmly in the future of AI.

Locking in the Chips

Here’s the thing: Intel and AMD are scrambling for scraps in AI, but Nvidia just guaranteed its chips will stay front and center.

You don’t need to wonder if demand shows up when you’ve already locked the biggest AI player into using your gear. That’s as close to certainty as this industry gets.

Why It Matters to You

A $100 billion price tag sounds insane. But if OpenAI keeps leading the field, Nvidia isn’t just the toolmaker.

It becomes the toll booth every AI company has to pass through. For you, that means Nvidia is setting up steady growth while rivals fight for leftovers.

Bottom line: Nvidia didn’t just buy stock. It bought the racetrack, the scoreboard, and maybe even the referee.

Pfizer (NYSE: PFE) just cut a $7.3 billion check for Metsera (NASDAQ: MTSR). The prize? Early-stage obesity drugs in a market that could be worth $150 billion by 2030. 

Right now, Eli Lilly and Novo Nordisk are running laps around everyone, but Pfizer clearly doesn’t plan to sit out the race.

Betting on Convenience

Metsera’s pipeline has two standouts: MET-097i, a GLP-1 injectable, and MET-233i, an amylin drug designed for once-a-month dosing. That’s the detail to watch.

If patients can lose weight without weekly needles, adoption skyrockets. And let’s be real — you’d pick the once-a-month option too.

Swing Big or Stay Irrelevant

Pfizer hasn’t exactly shone in weight-loss pills, so this buyout is them saying, “go big or go home.” Paying a 43% premium isn’t pocket change.

You have to ask yourself: Is this desperation or the exact kind of bold swing needed to claw back into relevance?

What’s on the Line

If it works, Pfizer jumps from laggard to serious contender, joining Lilly and Novo in the winner’s circle. If it flops, $7.3 billion just bought them another scar.

Either way, you’re watching a company take its shot in one of the hottest markets in medicine.

This brand's not Nike-and that's the point.

It's fast, tech-driven, and built for viral drops.

Now, it has equity backing from one of college sports' most iconic names.

Find out why Bama is betting on this company

GameStop (NYSE: GME) is back in the headlines, and for once, it’s not just Reddit noise.

The stock’s wild swings are still here, but underneath the chaos, the business actually showed some spark this year.

Collectibles, consoles, and yes, crypto, have turned the company’s earnings from “meh” to “hey, that’s not bad.”

Collectibles Craze Is Real

Remember when Target had to stop selling Pokémon cards because fights were breaking out? That craze has been spilling into GameStop’s stores, and the numbers prove it.

Collectibles revenue jumped 63% year over year to $228 million, turning dusty baseball cards into real business fuel. It’s not just cards either.

Hardware sales climbed 31%, and Bitcoin on the balance sheet now tops half a billion.

Say what you want about meme magic, but you can’t deny GameStop is finding ways to stay relevant.

This Rally Isn’t Just Twitter Hype

Earlier this year, shares spiked just because the CEO posted a photo with Michael Saylor. That hype train crashed fast, taking the stock back to $22.

This time, the rally came with a revenue beat and better margins, which is at least something you can hang your hat on.

Does that mean GME is suddenly safe? Not quite. The business is still small compared to its past, and crypto swings could whiplash the stock anytime.

If you’re holding, treat it like a trade, not a retirement plan.

GameStop is still a casino chip, but at least now it’s a casino chip backed by real sales, not just memes.

👉 Click here to get our closing report to your cell for free!

AgriFORCE Growing Systems Ltd [AGRI] $5.73 (+137.76%)

AgriFORCE surged after unveiling a dramatic pivot to become AVAX One, the first Nasdaq-listed Avalanche treasury company backed by major crypto investors.

MBX Biosciences Inc [MBX] $20.00 (+100.00%)

MBX Biosciences doubled on statistically significant Phase 2 data and positive 6-month results, positioning canvuparatide as a best-in-class hormone therapy ahead of a planned Phase 3 launch.

Qualigen Therapeutics Inc [QLGN] $5.53 (+94.72%)

Qualigen Therapeutics soared after Faraday Future revealed a $41 million strategic investment to pivot the company into a crypto-Web3 powerhouse under the new name CXC10.

Helius Medical Technologies Inc [HSDT] $16.02 (-33.61%)

Helius fell as investor enthusiasm cooled following its Solana treasury launch, with SOL dipping below the firm’s purchase price amid crypto volatility.

Cea Industries Inc [BNC] $7.80 (-19.50%)

Cea Industries shares fell after the company revealed a registration statement for PIPE and warrant deals, raising dilution concerns. Meanwhile, the price of the BNB coin it holds dropped sharply.

Compass Inc [COMP] $7.91 (-15.80%)

Compass sank after announcing a $10 billion all-stock merger with Anywhere Real Estate, raising dilution concerns among current shareholders.

On Behalf of The FUTR Corp.

Most “next big AI” stories are still burning cash.

But not this one.

The foundation is already in place:

Now comes the real catalyst.  The rollout of consumer AI agents.

Agents that can read your bills, flag your renewals, pay your obligations, and reward you for sharing your structured, verified data.

Every bill, contract, and policy hides valuable zero-party data. A new payments backbone combined with a Utility Token unlocks it, creating a consent-driven marketplace where every transaction generates recurring revenue.

This isn’t just another startup promise. It’s a scaled, profitable engine ready to tap one of the fastest-growing markets of the decade.

And right now, the market hasn’t priced it in.

Click here to get the name and stock symbol before it does.

*Examples that we provide of share price increases pertaining to a particular Issuer from one referenced date to another represent an arbitrarily chosen time period and are no indication whatsoever of future stock prices for that Issuer and are of no predictive value. Our stock profiles are intended to highlight certain companies for YOUR further investigation; they are NOT stock recommendations or constitute an offer or sale of the referenced securities.

That's it for today! Please, write us back, and let us know what you think of the Closing Bell Roundup. We're always eager to hear feedback!

Thanks for reading. I'll see you at the next open! 

Best Regards,
— Adam G.
Elite Trade Club

Click here to get our daily newsletter straight to your cell for free.

P.S. Just like this newsletter, it's 100% free*, and you can stop at any time by replying STOP.